Suprax (céfixime) - Sanofi Canada

43. Powell, M., Kentsia-Carouzou, C., Voutsinas, D., Williams, J.D. A comparison of the in vitroactivity of ampicillin and cefixime against 2458 clinical isolates of Haemophilus influenzae.Workshop, l5th International Congress of Chemotherapy, July, l987. Advances inExperimental and Clinical Chemotherapy l988; l: l5-l7.44. Risser, W.L., Barone, J.S., Clark, P.A., Simpkins, D.L. Noncomparative open labelmulticentre trial of cefixime for treatment of bacterial pharyngitis, cystitis, pneumonia inpediatric patients. Pediatric Infectious Disease l987; 6: l002-l006.45. Silber, D.M., Bohaychuk, W., Stout, M., Haynes, J.D., Schneider, J., Woodward, D.L., Look,Z.M., Weiss, A.I., Yacobi, A., Faulkner, R.D. Pharmacokinetics of cefixime in young andelderly volunteers. Workshop, l5th International Congress of Chemotherapy, July l987.Advances in Experimental and Clinical Chemotherapy l988; l: l8-20.46. Smith, S.M., Eng, R.H.K. Activity of Cefixime (FK027) for resistant gram-negative bacilli.Chemotherapy l988; 34: 455-46l.47. Stone, J.W., Liong, G., Andrews, J.M., Wise, R. Cefixime, in vitro activity, pharmacokineticsand tissue penetration. Journal of Antimicrobial Chemotherapy l989; 23: 22l-228.48. Tally, F.P., Desjardins, R.E., McCarthy, E.F., Cartwright, K. Safety profile of cefixime.Pediatric Infectious Disease l987; 6: 976-980.